We are live on ! Find out more
ANTX icon

AN2 Therapeutics
ANTX

36 hedge funds and large institutions have $92.9M invested in AN2 Therapeutics in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 23 increasing their positions, 3 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

667% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 3

1.37% more ownership

Funds ownership: 48.95% → 50.32% (+1.4%)

5% less funds holding

Funds holding: 38 → 36 (-2)

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

44% less capital invested

Capital invested by funds: $165M → $92.9M (-$72.1M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
36
Holders Change
-2
Holders Change %
-5.26%
% of All Funds
0.58%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
5
Increased
23
Reduced
3
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$5.42M
2
BlackRock
BlackRock
New York
+$3.44M
3
MIM
Monashee Investment Management
Massachusetts
+$2.9M
4
Northern Trust
Northern Trust
Illinois
+$581K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$533K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$12.5M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$767K
3
BI
BVF Inc
California
-$706K
4
Renaissance Technologies
Renaissance Technologies
New York
-$382K
5
PAM
Panagora Asset Management
Massachusetts
-$299K
Name Holding Trade Value Shares
Change 		Change in
Stake
California State Teachers Retirement System (CalSTRS)
26
California State Teachers Retirement System (CalSTRS)
California
$42.3K +$34K +2,541 +134%
SO
27
STRS Ohio
Ohio
$21K +$30.8K +2,300 New
AB
28
Amalgamated Bank
New York
$18K +$6.05K +452 +32%
Royal Bank of Canada
29
Royal Bank of Canada
Ontario, Canada
$17K +$22.7K +1,692 +2,868%
Legal & General Group
30
Legal & General Group
United Kingdom
$11.1K +$10.4K +775 +198%
TRCT
31
Tower Research Capital (TRC)
New York
$8K -$5.66K -423 -33%
AIP
32
Ameritas Investment Partners
Nebraska
$3.48K – – –
Fidelity Investments
33
Fidelity Investments
Massachusetts
$2.39K +$3.15K +235 +1,469%
Osaic Holdings
34
Osaic Holdings
Arizona
$2K – – –
PAG
35
Private Advisor Group
New Jersey
$105 +$147K +11,008 New
DM
36
Deerfield Management
New York
– -$12.5M -716,538 Closed
Renaissance Technologies
37
Renaissance Technologies
New York
– -$382K -22,000 Closed
PAM
38
Panagora Asset Management
Massachusetts
– -$299K -17,219 Closed
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
– -$292K -16,827 Closed
EMG
40
ETF Managers Group
New Jersey
– -$100K -5,726 Closed
Nisa Investment Advisors
41
Nisa Investment Advisors
Missouri
– +$134 +10 New
1
2

ANTX Hedge Fund Activity: Q4 2022 in Review

36 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q4 2022, worth a combined $92.9M — down 44% from $165M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of ANTX and 5 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 23 added.

The largest buyer was Vanguard Group, adding an estimated $5.42M. The largest seller was Deerfield Management, exiting entirely with an estimated $12.5M sold.

  • 36 institutional investors held AN2 Therapeutics (ANTX) as of Q4 2022, down from 38 in Q3 2022.
  • Funds reported $92.9M of AN2 Therapeutics stock for Q4 2022, down 44% quarter-over-quarter.
  • 5 funds opened new AN2 Therapeutics positions in Q4 2022 and 7 closed out, a net change of -2 holders.
  • The largest AN2 Therapeutics buyer in Q4 2022 was Vanguard Group, an estimated $5.42M added.
  • The largest AN2 Therapeutics seller in Q4 2022 was Deerfield Management, an estimated $12.5M sold.

Based on aggregated 13F filings for Q4 2022.